{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:52:02Z","timestamp":1784019122255,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.bbmt.2015.05.013","type":"journal-article","created":{"date-parts":[[2015,5,30]],"date-time":"2015-05-30T04:42:35Z","timestamp":1432960955000},"page":"1823-1829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results\u2013Medicare Database"],"prefix":"10.1016","volume":"21","author":[{"given":"Gunjan L.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron N.","family":"Winn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Jung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kellie A.","family":"Sprague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedy P.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Buchsbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua T.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Comenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2015.05.013_bib1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"Kyle","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2015.05.013_bib2","series-title":"SEER Cancer Statistics Review, 1975-2011","author":"Howlader","year":"2014"},{"key":"10.1016\/j.bbmt.2015.05.013_bib3","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.05.013_bib4","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1634\/theoncologist.2011-0229","article-title":"Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data","volume":"16","author":"Pulte","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.bbmt.2015.05.013_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A\u00a0prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma","volume":"355","author":"Attal","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.05.013_bib6","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.05.013_bib7","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.bbmt.2013.08.002","article-title":"Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma","volume":"19","author":"Costa","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.05.013_bib8","unstructured":"Pasquini M, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2013. Available at: http:\/\/www.cibmtr.org. Accessed December 1, 2014."},{"key":"10.1016\/j.bbmt.2015.05.013_bib9","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2012.46.3323","article-title":"Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States","volume":"31","author":"Warren","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.05.013_bib10","series-title":"Procedures with the most rapidly increasing hospital costs, 2004-2007. Statistical brief 82. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]","author":"Stranges","year":"2009"},{"key":"10.1016\/j.bbmt.2015.05.013_bib11","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1182\/blood-2012-05-426783","article-title":"Economics of hematopoietic cell transplantation","volume":"120","author":"Khera","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2015.05.013_bib12","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/bmt.2012.133","article-title":"Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large national private claims database","volume":"48","author":"Majhail","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.05.013_bib13","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/ctr.12421","article-title":"Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma","volume":"28","author":"Pandya","year":"2014","journal-title":"Clin Transplant"},{"key":"10.1016\/j.bbmt.2015.05.013_bib14","doi-asserted-by":"crossref","first-page":"e16569","DOI":"10.1200\/jco.2011.29.15_suppl.e16569","article-title":"Cost differences among treatment options for patients with refractory myeloma previously treated with high-dose chemotherapy and autologous stem-cell transplantation: an analysis from the U.S. and Swiss perspectives","volume":"29","author":"Blank","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2015.05.013_bib15","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/00001813-199811000-00008","article-title":"Costs of intensive treatment and follow-up of patients with multiple myeloma","volume":"9","author":"Buijt","year":"1998","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.bbmt.2015.05.013_bib16","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.bbmt.2012.12.006","article-title":"Safety and cost-effectiveness of\u00a0outpatient autologous stem cell transplantation in patients with multiple myeloma","volume":"19","author":"Holbro","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.05.013_bib17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.bmt.1700900","article-title":"Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma","volume":"20","author":"Jagannath","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2015.05.013_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3109\/10428190309178811","article-title":"Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma","volume":"44","author":"Kouroukis","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2015.05.013_bib19","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/j.ejca.2005.11.036","article-title":"An update: health economics of managing multiple myeloma","volume":"42","author":"Moeremans","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bbmt.2015.05.013_bib20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00019053-199916040-00002","article-title":"Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations","volume":"16","author":"Wisl\u00f8ff","year":"1999","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.bbmt.2015.05.013_bib21","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.ejca.2011.04.005","article-title":"Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodology","volume":"47","author":"Gaultney","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bbmt.2015.05.013_bib22","article-title":"Comparison of SEER treatment data with Medicare claims","author":"Noone","year":"2014","journal-title":"Med Care"},{"key":"10.1016\/j.bbmt.2015.05.013_bib23","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/00005650-199308000-00006","article-title":"Potential for cancer related health services research using a linked Medicare-tumor registry database","volume":"31","author":"Potosky","year":"1993","journal-title":"Med Care"},{"key":"10.1016\/j.bbmt.2015.05.013_bib24","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.bbmt.2015.05.013_bib25","unstructured":"Parsons L. Performing a 1:N case-control match on propensity score. Proceedings of the 29th Annual SAS Users Group International Conference. Montreal, Canada. 2004. Accessed December 1, 2014. Available at: http:\/\/www2.sas.com\/proceedings\/sugi29\/165-29.pdf."},{"key":"10.1016\/j.bbmt.2015.05.013_bib26","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/jnci\/djq393","article-title":"Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data","volume":"102","author":"Hadley","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.bbmt.2015.05.013_bib27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Amer Stat Assn"},{"key":"10.1016\/j.bbmt.2015.05.013_bib28","doi-asserted-by":"crossref","first-page":"IV-104","DOI":"10.1097\/00005650-200208001-00014","article-title":"Estimating health care costs related to cancer treatment from SEER-Medicare data","volume":"40","author":"Brown","year":"2002","journal-title":"Med Care"},{"key":"10.1016\/j.bbmt.2015.05.013_bib29","series-title":"Cost-Effectiveness in Health and Medicine","year":"1996"},{"key":"10.1016\/j.bbmt.2015.05.013_bib30","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.05.013_bib31","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.05.013_bib32","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2015.05.013_bib33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000357394","article-title":"Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network","volume":"132","author":"Ozaki","year":"2014","journal-title":"Acta Haematol"},{"key":"10.1016\/j.bbmt.2015.05.013_bib34","first-page":"1475","article-title":"Treatments for newly diagnosed multiple myeloma: analysis of survival data and cost-effectiveness evaluation","volume":"5","author":"Trippoli","year":"1998","journal-title":"Oncol Rep"},{"key":"10.1016\/j.bbmt.2015.05.013_bib35","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1034\/j.1600-0609.2001.066005328.x","article-title":"Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma","volume":"66","author":"Gulbrandsen","year":"2001","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2015.05.013_bib36","doi-asserted-by":"crossref","first-page":"e75047","DOI":"10.1371\/journal.pone.0075047","article-title":"Long term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysis","volume":"8","author":"Corso","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbmt.2015.05.013_bib37","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.ejca.2004.01.019","article-title":"A\u00a0cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II\/III multiple myeloma; a prospective randomised phase","volume":"40","author":"Van Agthoven","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bbmt.2015.05.013_bib38","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.3324.3324","article-title":"A\u00a0budget impact model comparing resource utilization of four approved therapies for multiple myeloma (MM) in the US","volume":"110","author":"Fullerton","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bbmt.2015.05.013_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv139","article-title":"The real world effectiveness of hematopoietic transplant among elderly individuals with multiple myeloma","volume":"107","author":"Winn","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bbmt.2015.05.013_bib40","first-page":"1086","article-title":"Do value thresholds for oncology drugs differ from nononcology drugs?","volume":"20","author":"Bae","year":"2014","journal-title":"J\u00a0Manag Care Pharm"},{"key":"10.1016\/j.bbmt.2015.05.013_bib41","unstructured":"About the SEER Program. Surveill Res Program, NCI. Available at: http:\/\/seer.cancer.gov\/about\/overview.html. Accessed December 1, 2014."},{"key":"10.1016\/j.bbmt.2015.05.013_bib42","unstructured":"Measures that are limited or not available in the data. NCI. Available at: http:\/\/appliedresearch.cancer.gov\/seermedicare\/considerations\/measures.html. Accessed December 1, 2014."},{"key":"10.1016\/j.bbmt.2015.05.013_bib43","series-title":"Require SEER Site Specific Factors for Collaborative Stage","year":"2014"},{"key":"10.1016\/j.bbmt.2015.05.013_bib44","first-page":"19","article-title":"Economic and clinical impact of multiple myeloma to managed care","volume":"14","author":"Cook","year":"2008","journal-title":"J\u00a0Manag Care Pharm"},{"key":"10.1016\/j.bbmt.2015.05.013_bib45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1634\/theoncologist.2012-0113","article-title":"Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data","volume":"18","author":"Teitelbaum","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.bbmt.2015.05.013_bib46","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1634\/theoncologist.2011-0380","volume":"18","author":"Garrison","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.bbmt.2015.05.013_bib47","first-page":"319","article-title":"To transplant of not to transplant in multiple myeloma","volume":"12","author":"Giralt","year":"2014","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.bbmt.2015.05.013_bib48","doi-asserted-by":"crossref","first-page":"IV-3","DOI":"10.1097\/00005650-200208001-00002","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115003365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879115003365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:51:13Z","timestamp":1761058273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879115003365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":48,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S1083879115003365"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.05.013","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results\u2013Medicare Database","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2015.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}